Diagnostic evaluation of the erectile function domain of the international index of erectile function


      Objectives. To evaluate the erectile function (EF) domain of the International Index of Erectile Function (IIEF) as a diagnostic tool to discriminate between men with and without erectile dysfunction (ED) and to develop a clinically meaningful gradient of severity for ED.
      Methods. One thousand one hundred fifty-one men (1035 with and 116 without ED) who reported attempting sexual activity were evaluated using data from four clinical trials of sildenafil citrate (Viagra) and two control samples. The statistical program Classification and Regression Trees was used to determine optimal cutoff scores on the EF domain (range 6 to 30) to distinguish between men with and without ED and to determine levels of ED severity on the EF domain using the IIEF item on sexual intercourse satisfaction.
      Results. For a 0.5 prevalence rate of ED, the optimal cutoff score was 25, with men scoring less than or equal to 25 classified as having ED and those scoring above 25 as not having ED (sensitivity 0.97, specificity 0.88). Sensitivity analyses revealed a robust statistical solution that was well supported with different assumed prevalence rates and several cross-validations. The severity of ED was classified into five categories: no ED (EF score 26 to 30), mild (EF score 22 to 25), mild to moderate (EF score 17 to 21), moderate (EF score 11 to 16), and severe (EF score 6 to 10). Substantial agreement was shown between these predicted and “true” classes (weighted kappa 0.80).
      Conclusions. The EF domain possesses favorable statistical properties as a diagnostic tool, not only in distinguishing between men with and without ED, but also in classifying levels of ED severity. Clinical validation with self-rated assessments of ED severity is warranted.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Urology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Rosen R.C
        • Riley A
        • Wagner G
        • et al.
        The International Index of Erectile Function (IIEF): a multidimensional scale for assessment of erectile dysfunction.
        Urology. 1997; 49: 822-830
      1. Goldstein I, Lue TF, Padma-Nathan H, et al: for the Sildenafil Study Group: Oral sildenafil in the treatment of erectile dysfunction. N Engl J Med 338: 1397–1404, 1998.

      2. Goldstein I, and the Vasomax Study Group: Efficacy and safety of oral phentolamine (Vasomax) for the treatment of minimal erectile dysfunction. J Urol 159(suppl): 240, 1998.

        • Feldman H.A
        • Goldstein I
        • Hatzichristou D.G
        • et al.
        Impotence and its medical and psychosocial correlates: results of the Massachusetts male aging study.
        J Urol. 1994; 151: 54-61
        • Feldman H.A
        • Goldstein I
        • Hatzichristou D.G
        • et al.
        Construction of a surrogate variable for impotence in the Massachusetts Male Aging Study.
        J Clin Epidemiol. 1994; 47: 457-467
        • O’Leary M.P
        • Fowler F.J
        • Lenderking W.R
        • et al.
        A brief male sexual function inventory for urology.
        Urology. 1995; 46: 697-706
        • NIH Consensus Development Panel on Impotence
        JAMA. 1993; 270: 83-90
        • Cappelleri J.C
        • Rosen R.C
        • Smith M.D
        • et al.
        Some developments on the International Index of Erectile Function (IIEF).
        Drug Inf J. 1999; 33: 179-190
        • Steinberg D
        • Colla P
        CART. Salford Systems, San Diego1995
      3. Breiman L, Friedman J, Olshen R, et al: Classification and Regression Trees. Pacific Grove, Wadsworth, 1984.

        • Benet A.E
        • Melman A
        The epidemiology of erectile dysfunction.
        Urol Clin North Am. 1995; 22: 699-709
      4. SAS Institute: SAS/STAT® User’s Guide, version 6, 4th ed. Cary, North Carolina, SAS Institute, 1990, vol 2, p 944.

      5. Weinstein MC, Fineberg HV, Elstein AS, et al: Clinical Decision Analysis. Philadelphia, WB Saunders, 1980, pp 75–130.

      6. Dawson-Saunders B, and Trapp RG: Basic & Clinical Biostatistics, 2nd ed. Norwalk, Connecticut, Appleton & Lange, 1994, pp 232–248.

        • Cohen J
        A coefficient of agreement of nominal scales.
        Educ Psychol Meas. 1960; 20: 37-46
        • Cohen J
        Weighted kappa: nominal scale agreement with provision for scaled disagreement or partial credit.
        Psychol Bull. 1968; 70: 213-220
      7. StatXact 3 for Windows: Statistical Software for Exact Nonparametric Inference User Manual. Cambridge, CYTEL Software Corporation, 1995, pp 399–401, 639–663, 675–680.

      8. Siegel S, and Castellan NJ: Nonparametric Statistics for the Behavioral Sciences, 2nd ed. New York, McGraw-Hill, 1988, pp 235–254.

        • Lamm S
        • Couzens G.S
        The Virility Factor. Simon & Schuster, New York1998: 98